ClinicaliQ Trial Snapshot
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting • Phase III • NCT06290141.
- Riliprubart compared to standard IVIg treatment in adults with CIDP over 109 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up. Conditions: Chronic Inflammatory Demyelinating Polyneuropathy Interventions: riliprubart, Placebo, riliprubart, Placebo, IVIg, Placebo Lead Sponsor: Sanofi Planned Enrollment: 160 participants